EDIT-301 preclinical data support differentiated approach to develop a transformative medicine for people living with transfusion-dependent beta thalassemia
Preclinical data demonstrating proprietary CRISPR/Cas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH), being held in Atlanta and virtually, December 11-14, 2021. The two abstracts outline preclinical data from the Companys hemoglobinopathy and oncology programs. An additional oncology program abstract was published in Blood, the flagship journal of the American Society of Hematology.
Editas Medicine presentations at ASH will include preclinical data demonstrating that:
Edited peripheral blood CD34+ cells mobilized from transfusion-dependent beta thalassemia (TDT) patients demonstrated significantly improved red blood cell production and increased hemoglobin content, supporting the development of EDIT-301 for the treatment of TDT; and
Induced pluripotent stem cells (iPSC)-derived natural killer cells (iNKs), edited with proprietary CRISPR/Cas12a to double knock-out (DKO) CISH and TGFR2, demonstrated robust tumor reduction in vivo as compared to wild type iNKs, supporting the development of DKO iNKs as a potent allogeneic cell-based medicine for cancer.
At ASH, we will present preclinical data from our EDIT-301 program that reinforces our belief that our differentiated therapeutic strategy leveraging our highly-specific engineered Cas12a enzyme with more physiologic targeting has great potential for transfusion-dependent beta thalassemia. We believe that EDIT-301 has the potential to be an efficacious autologous cell therapy for TDT, and we remain on track to file an IND by year-end, said Mark S. Shearman, Ph.D., Chief Scientific Officer, Editas Medicine. We will also share early exciting preclinical data showcasing how we are using our proprietary gene editing tools to produce a customized iNK cell that we believe will have highly potent activity across multiple tumor cell killing mechanisms and superior persistence. These data reinforce our view that we have a unique and highly promising allogeneic approach with the potential to treat a wide range of solid tumors.
Story continues
The complete list of Editas Medicine presentations is below. Abstracts can be accessed on the ASH website and the presentations will be posted on the Editas Medicine website during the conference.
Poster Presentations:Title: Preclinical Development of EDIT301, an Autologous Cell Therapy Comprising AsCas12a-RNP Modified Mobilized Peripheral Blood-CD34+ Cells for the Potential Treatment of Transfusion Dependent Beta ThalassemiaDate and Time: Saturday, December 11, 2021, 5:30 p.m. 7:30 p.m. EST Session Name: 801. Gene Therapies: Poster I Location: Georgia World Congress Center, Hall B5
Title: Deletion of CISH and TGFR2 in iPSC-Derived NK Cells Promotes High Cytotoxicity and Enhances In Vivo Tumor KillingDate and Time: Sunday, December 12, 2021, 6:00 p.m. 8:00 p.m. ESTSession Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II Location: Georgia World Congress Center, Hall B5
About EDIT-301EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 is comprised of sickle patient (for SCD) or normal donor (for TDT) CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) that targets the HBG1 and HBG2 promoters in the beta-globin locus where naturally occurring fetal hemoglobin (HbF) inducing mutations reside. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in HbF production, which has the potential to provide a one-time, durable treatment benefit for people living with sickle cell disease and TDT.
About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.
Forward-Looking StatementsThis press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Companys product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in the Companys most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Companys subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
- CIRI calls for safety advice revamp after health concerns raised by 3D printing emission research - 3D Printing Industry - October 13th, 2022
- Global Adult Stem Cells Market | Expected to Reach USD 9.45 Billion and Compound Annual Growth Rate (CAGR) is - openPR - October 4th, 2022
- The cloudy connection between fragile X and cancer - Spectrum - October 4th, 2022
- CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors - The Fresh Toast - June 22nd, 2022
- How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into 'Safer' Covid-19 Vaccines: Study - ABP Live - June 4th, 2022
- SpaceX capsule returns to Earth with first all-private space station crew Spaceflight Now - Spaceflight Now - May 2nd, 2022
- Identifying Missing Links - and Why Certain Drugs Don't Work - in Alzhiemer's - BioSpace - April 6th, 2022
- Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies - Business Wire - March 25th, 2022
- Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - GlobeNewswire - December 24th, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and... - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual... - November 8th, 2021
- Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and... - November 8th, 2021
- Role of Stem Cells in Treatment of Neurological Disorder - October 16th, 2021
- A plant that 'cannot die' reveals its genetic secrets - The Independent - August 5th, 2021
- Exploring science with a new generation of girls - US Embassy in Georgia - February 11th, 2021
- Stemcell Renewal Elixir GEORGIA LOUISE - September 25th, 2020
- COVID is shifting the conversation about the medical application of CBD - Open Access Government - September 22nd, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 22nd, 2020
- Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer - Yahoo... - June 6th, 2020
- Athens hospital using biologic treatment on COVID-19 patients - Online Athens - June 2nd, 2020
- Study reveals birth defects caused by flame retardant - University of Georgia - June 2nd, 2020
- Novant Health Initiates Phase 2b/3 Trial with CytoDyns Leronlimab for Severely and Critically Ill COVID-19 Patients - Yahoo Finance - May 11th, 2020
- CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -... - May 5th, 2020
- Covid-19 has shuttered labs. It could put a generation of researchers at risk - STAT - May 5th, 2020
- CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable... - May 5th, 2020
- Stem Cell Therapy in Atlanta, GA - sipapain.com - February 3rd, 2020
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 - News Distribute - December 27th, 2019
- Transition to exhaustion: clues for cancer immunotherapy - 7thSpace Interactive - December 5th, 2019
- Autologous Stem Cell And Non Stem Cell Based Therapies Market Opportunity Analysis and Industry Forecast up to 2026 - Guru Online News - November 20th, 2019
- Georgia solar factory scores on tariffs; others in industry take a hit - Atlanta Journal Constitution - September 23rd, 2019
- Georgia Stem Cells | Stem Cell TV - September 7th, 2019
- Current Strategies and Challenges for Purification of ... - March 6th, 2019
- Stem Cell Savannah Georgia 31401 - January 20th, 2019
- Atlanta, Georgia Stem Cell Transplant, Marietta, Berkeley ... - September 7th, 2018
- Placenta | Amniotic tissue is not stem cell therapy - Dr ... - July 17th, 2018
- Turning Skin Cells Into Brain Cells - 06/28/2012 - October 1st, 2017
- This Wasp's Larvae Sometimes Grow Hundreds of Soldier ClonesBut Why? - Entomology Today - August 21st, 2017
- Atlanta Stem Cell Therapy | Georgia Stem Cell Treatments ... - October 7th, 2016
- Storing Stem Cells In Teeth For Your Familys Future Health - October 31st, 2015
- Scientists Turn Back the Clock on Adult Stem Cells Aging ... - October 16th, 2015
- Lymphoid Cells, Lymphoid Stem Cells - AllCells.com - October 11th, 2015
- Using Stem Cells in Teeth for Future Use in Developing ... - September 30th, 2015
- Human Mesenchymal Stem Cells & Media - September 25th, 2015
- Asymmetrex Plans to Report Results From Adult Stem Cell ... - August 2nd, 2015
- Stem Cells - Lonza - July 10th, 2015
- Global Stem Cells Group Announces First Stem Cell Training ... - June 3rd, 2015
- Effective Hematopoietic Mesenchymal Stem Cell Therapies - April 25th, 2015
- Stem Cells Hashimoto's Thyroiditis - April 22nd, 2015
- Welcome to Atlanta Stem Cell Treatment - April 9th, 2015
- Stem Cells Thailand - Stem Cell Therapy Thailand - March 27th, 2015
- Stem Cell Institute Los Angeles Chronic Pain Treatments - March 27th, 2015
- Graphene Shows Promise In Eradication Of Stem Cancer Cells - March 10th, 2015
- Stem Cell Treatment India,Stem Cell Treatment India,Cost ... - March 8th, 2015
- Bone Marrow & Stem Cell Transplant Center | Atlanta, GA ... - November 16th, 2014
- Biological fat with a sugar attached essential to maintaining the brain's supply of stem cells - November 3rd, 2014
- How stress ups depression risk - October 21st, 2014
- Protein appears to protect against bone loss in arthritis - September 13th, 2014
- Boron Facilitates Stem Cell Growth and Development in Corn - August 29th, 2014
- Georgia (Stem Cell) - what-when-how - August 26th, 2014
- Stem Cells in GA - Georgia Bio - August 25th, 2014
- Stem Cells COPD | Stem Cell Treatments - August 23rd, 2014
- Stem Cells Atlanta GA, Stem Cell Therapy, Dental Stem Cells - August 22nd, 2014
- Stem cells reveal how illness-linked genetic variation affects neurons - August 22nd, 2014